Zobrazeno 1 - 10
of 98
pro vyhledávání: '"ERZSÉBET, RÁSÓ"'
Autor:
Maja L. Nádorvári, István Kenessey, András Kiss, Tamás Barbai, Janina Kulka, Erzsébet Rásó, József Tímár
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-9 (2024)
Abstract Background The tumor-agnostic indication of immune checkpoint inhibitors to treat cancers with mismatch repair deficiency (dMMR)/microsatellite instability (MSI) increased the demand for such tests beyond Lynch syndrome. International guidel
Externí odkaz:
https://doaj.org/article/6f9fd537767a43c59925ca3027cb0b22
Autor:
Andrea Ladányi, Erzsébet Rásó, Tamás Barbai, Laura Vízkeleti, László G. Puskás, Szonja A. Kovács, Balázs Győrffy, József Tímár
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 5, p 2704 (2022)
We developed a human melanoma model using the HT168-M1 cell line to induce IFN-α2 resistance in vitro (HT168-M1res), which was proven to be maintained in vivo in SCID mice. Comparing the mRNA profile of in vitro cultured HT168-M1res cells to its sen
Externí odkaz:
https://doaj.org/article/0f012256ff3441bc95681d8f920cd987
Autor:
Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba, Gabriella Gálffy, Ülkü Yilmaz Turay, Ahmet Demirkazik, Gunta Purkalne, Attila Somfay, Zsolt Pápai-Székely, Erzsébet Rásó, Gyula Ostoros
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine clinical
Externí odkaz:
https://doaj.org/article/d7176d935e0a4a359302b37df3fb11e5
Autor:
Mihály Cserepes, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, István Kenessey, Árpád Szöőr, György Vereb, Éva Remenár, József Tóvári
Publikováno v:
Cancers; Volume 14; Issue 10; Pages: 2407
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the
Autor:
LILLA, NÁDORVÁRI MAJA, ANDRÁS, KISS, TAMÁS, BARBAI, JANINA, KULKA, ERZSÉBET, RÁSÓ, JÓZSEF, TÍMÁR
Publikováno v:
Magyar Onkologia; 2023, Vol. 67 Issue 2, p147-153, 7p
Autor:
Erzsébet Rásó
Publikováno v:
Cancer Metastasis Reviews
One of the mechanisms potentially explaining the discrepancy between the number of human genes and the functional complexity of organisms is generating alternative splice variants, an attribute of the vast majority of multi-exon genes. Members of the
Frequent KIT mutations in skin lesions of patients with BRAF wild-type Langerhans cell histiocytosis
Autor:
Csaba Bödör, Béla E. Tóth, Judit Csomor, Sarolta Kárpáti, József Tímár, Norbert Kiss, Judit Hársing, Erzsébet Rásó
Publikováno v:
Virchows Archiv
Langerhans cell histiocytosis (LCH) is characterized by mutations of the RAS-RAF-MAPK signaling pathway. We analyzed MAP2K1, NRAS and KIT mutation incidence in skin lesions of BRAF wild-type (wt) LCH patients. We evaluated the occurrence of MAP2K1, N
Autor:
Adél Kárpáti, Mihály Cserepes, László Őrfi, Györgyi A. Nelhűbel, Zita Hegedűs, József Tóvári, Erzsébet Rásó, Judit Dobos, Bálint Szokol, Tamás Barbai, Balázs Szabó, Dóra Türk, Viktoria Laszlo, István Kenessey
Publikováno v:
Pathology and Oncology Research
Background: Anti-EGFR antibody therapy is still one of the clinical choices in head and neck squamous cell carcinoma (HNSCC) patients, but the emergence of cetuximab resistance questioned its effectiveness and reduced its applicability. Although seve
Autor:
Erzsébet Rásó, Zoltán Sápi, Béla Iványi, Janina Kulka, Levente Kuthi, Brigitta Vrabély, Alex Jenei, Zoltán Bajory, Tamás Micsik, Áron Somorácz, Adrienn Hajdu
Publikováno v:
Pathology Oncology Research
Thirty-one cases of low-grade renal cell carcinoma (RCC) with clear cells and tubulopapillary/papillary architecture were analyzed retrospectively with immunohistochemical and genetic markers to gain more experience with the differential diagnosis of
Autor:
Z. Burián, Violetta Piurkó, A. Ladányi, Erzsébet Rásó, József Tímár, Tamás Barbai, Tamás Garay
Publikováno v:
Pathology & Oncology Research. 26:673-679
Zinc as an essential trace metal is a ubiquitous component of various molecules of the cell. Studies indicated that it may modulate functions of various cancer cell types, and can even inhibit metastasis formation in experimental models. In melanoma,